Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes

Fig. 3

Summary of NFE2L2 Nrf2-activating mutations in the MSK MetTropism cohort. (A) Distribution of NFE2L2 mutations according to locations of the mutation. (B) The prevalence of Nrf2-activating mutations and Nrf2-inactivating mutations in each cancer type. (C) Kaplan–Meier survival curves of OS among Nrf2-activating mutations, Nrf2-inactivating mutations, unknown NFE2L2 mutations and WT groups. (D) Association of Nrf2-inactivating mutations with OS stratified by cancer type. (E) The multivariate Cox regression analysis for OS in patients. MSI: microsatellite instability; FGA: fraction genome altered; OS: overall survival; MU: mutation; WT: wild type

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us